Key Insights on Gross Profit: Regeneron Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.

Regeneron vs. BioCryst: A Decade of Gross Profit Insights

__timestampBioCryst Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014134860002614539000
Thursday, January 1, 2015463610003711019000
Friday, January 1, 2016236540004560733000
Sunday, January 1, 2017234840005475166000
Monday, January 1, 2018201820006276700000
Tuesday, January 1, 2019447340007081200000
Wednesday, January 1, 2020161360007377200000
Friday, January 1, 202114990600013634200000
Saturday, January 1, 202226423300010612500000
Sunday, January 1, 202332675100011301400000
Monday, January 1, 202412231500000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: Regeneron vs. BioCryst

In the competitive landscape of biotechnology, Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, Regeneron has consistently outperformed BioCryst, with its gross profit peaking at over $13.6 billion in 2021, a staggering 4,000% higher than BioCryst's peak in 2023. This disparity highlights Regeneron's robust market position and successful product pipeline.

BioCryst, while showing growth, particularly in recent years, remains a smaller player. Its gross profit increased by over 2,300% from 2014 to 2023, indicating potential for future expansion. The data underscores the importance of strategic innovation and market adaptation in the biotech sector. As these companies continue to evolve, investors and industry watchers should keep a keen eye on their financial health and strategic moves.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025